Physician profile
Robert Boyd
NPI 1801869458
$9,525.57
in general payments reported to CMS, 2019-2025
21 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,723 · 2020: $2,330 · 2021: $1,797 · 2022: $1,647 · 2023: $824 · 2024: $101 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,512.18 | 2019-2024 | Enbrel, Otezla, Amjevita |
| E.R. Squibb & Sons, L.L.C. | $1,210.61 | 2019-2023 | Orencia |
| Novartis Pharmaceuticals Corporation | $982.56 | 2019-2025 | |
| Abbvie INC. | $947.81 | 2019-2023 | Skyrizi, Humira, Rinvoq |
| Janssen Biotech, INC. | $865.65 | 2019-2023 | Tremfya |
| Lilly USA, LLC | $829.47 | 2019-2025 | Taltz |
| Ucb, INC. | $742.66 | 2019-2025 | Cimzia, Bimzelx |
| Genentech USA, INC. | $360.80 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $209.06 | 2019-2020 | |
| Pfizer INC. | $183.90 | 2019 | |
| Celgene Corporation | $160.64 | 2019 | |
| Glaxosmithkline, LLC. | $139.21 | 2021-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $92.76 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $90.22 | 2019 | |
| Gilead Sciences, INC. | $38.41 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medexus Pharma, INC. | $37.24 | 2019 | |
| Mallinckrodt Enterprises LLC | $36.02 | 2019 | |
| Antares Pharma, INC. | $27.42 | 2019 | |
| Sandoz INC. | $24.56 | 2023 | |
| Organon LLC | $17.92 | 2023 | Hadlima |
| Portola Pharmaceuticals, LLC | $16.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.